

## Freedom of Information Request: Our Reference CTMUHB\_192\_22

### You asked:

1. How many patients over the last 4 months (January to April 2022) have received the following anti-VEGF treatments for any eye condition:

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Ranibizumab

2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Ranibizumab

3. Please provide the number of patients treated for Diabetic Macular Oedema (DMO) ONLY in the last 4 months (January to April 2022) with the following:

- Aflibercept
- Bevacizumab
- Dexamethasone
- Ranibizumab

4. Please provide the number of patients treated for Retinal Vein Occlusion (RVO) ONLY in the last 4 months (January to April 2022) with the following:

- Aflibercept
- Bevacizumab
- Dexamethasone
- Ranibizumab

### Our response:

Under section 21 of the Act, Cwm Taf Morgannwg University Health Board is not required to provide information in response to a request if it is already reasonably accessible to you. Responses are published via our [Disclosure Log](#) on the [Cwm Taf Morgannwg University Health Board](#) web site.

For ease of access, we have attached a link directly to the information below:

- [CTMUHB 184 22](#)